This clinical trial is testing a new drug called HB-2121, used as a diagnostic tool for celiac disease. Celiac disease is an illness where eating gluten (a protein found in wheat, barley, and rye) causes problems in the small intestine. The study will evaluate how safe a single dose of HB-2121 is and how the body handles it. Participants will take one oral dose and be monitored for 30 days. They need to visit the clinic 4 times and have 2 remote check-ins. They'll also answer a daily survey for a week about their health.
Key Points:
- Study duration: 30 days with 4 in-person and 2 remote visits.
- Participants receive a single oral dose of HB-2121.
- Must be healthy, aged 18+, and able to eat gluten without issues, if not celiac.
To join, participants should not have serious health issues or be pregnant. Those with celiac must have a confirmed diagnosis. The study checks for any side effects and measures the drug in the blood over time.
How understandable was the trial content above?
Hard to understand
Easy to understand